Status | Study |
Completed |
Study Name: An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects Condition: Orphan Cholestatic Liver Diseases Progressive Familial Intrahepatic Ch Date: 2017-02-27 Interventions: Drug: 3 mg [14C]-A4250 capsule Each subject will receive a single administration of 3 mg [14C]-A4250 cap |
Not yet recruiting |
Study Name: Metformin in Intrahepatic Cholestasis of Pregnancy Condition: Intrahepatic Cholestases Pregnancy Complications Date: 2016-12-22 Interventions: Drug: Metformin Metformin Hydr |
Completed |
Study Name: A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384 Condition: Orphan Cholestatic Liver Diseases Primary Biliary Cirrhosis Date: 2016-11-01 Interventions: Drug: A4250 Drug: CRC (A3384) |
Recruiting |
Study Name: Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital Condition: Cholangitis Liver Cirrhosis, Biliary Cholestasis Date: 2016-09-06 |
Completed |
Study Name: Impact of Cyclic Prolonged Parenteral Nutrition in Neonates Condition: Cholestasis in Newborn Date: 2015-12-16 Interventions: Procedure: Cyclic parenteral nutrition Cyclic parenteral nutrition was provided according to a method de |
Recruiting |
Study Name: Serum Autotaxin Levels in Cholestasis of Pregnancy Condition: Intrahepatic Cholestasis of Pregnancy Date: 2015-06-21 |
Completed |
Study Name: Study With Heptral in Subjects With Liver Disease Due to Alcohol Consumption Condition: Intrahepatic Cholestasis Associated With Alcoholic Liver Disease Date: 2014-07-21 Interventions: Drug: Ademetionine IV+tablet I |
Completed |
Study Name: Apoptosis May Have a Role in Etiopathogenesis of Obstetric Cholestasis. Condition: Pregnancy Date: 2014-07-12 |
Completed |
Study Name: Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease Condition: Alagille Syndrome Progressive Familial Intrahepatic Cholestasis Date: 2014-05-01 |
Temporarily not available |
Study Name: Expanded Access Protocol for an Intermediate Size Population - RAVICTI for Byler Disease Condition: Byler Disease Date: 2014-03-19 Interventions: Drug: RAVICTI open label expanded access protocol of titrated dosing regimen of RAVICTI for up to 60 wee |